
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVA.HTI,ChAdOx1.HTI,Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Gilead Buys HIV Vaccine from Biotech Following Clinical Collab
Details : The acquisition of the investigational assets for the HTI therapeutic vaccine, MVA.HTI, by Gilead Sciences marks a milestone in HIV research.
Product Name : MVA.HTI
Product Type : Vaccine
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : MVA.HTI,ChAdOx1.HTI,Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Vesatolimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Fundación FLS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Fundación FLS
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ChAdOx1.HTI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ChAdOx1.HTI is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : ChAdOx1.HTI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DNA.HTI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DNA.HTI is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 02, 2017
Lead Product(s) : DNA.HTI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
